Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Positive outcomes associated with stem cell transplantation in pediatric/AYA patients who receive FLAG-IDA-venetoclax for high-risk AML

View Full Paper
Ask AI
Bookmark
Share

Authors

ISIrtiza SheikhThe University of Texas MD Anderson Cancer CenterRRReeja RajMemorial HermannSCSamanta CatuenoPediatric Oncology Group

Discussion

Loading...

Member takes

Overview

Retrospective review shows FLAG-IDA-venetoclax improves remission and maintains low GVHD risk in pediatric AML.

Key Points

  • This study evaluates the outcomes of stem cell transplantation following FLAG-IDA-venetoclax treatment in pediatric and young adults with high-risk AML.
  • Conducted a retrospective chart review at MD Anderson Cancer Center.
  • Evaluated adverse events, engraftment, GVHD rates, and infectious complications.
  • Assessed response using International Working Group Criteria and MRD by flow cytometry.
  • 83% of patients underwent matched unrelated donor SCT.
  • Median time to neutrophil engraftment was 16.5 days, platelet engraftment was 26.5 days.
  • All patients demonstrated CD3, CD8, CD19, and NK cell levels consistent with immune reconstitution.

Cite This Study

Sheikh et al. (2025) studied this question.

synapsesocial.com/papers/69362f4e4fa91c937236d88chttps://doi.org/10.1182/blood-2025-5156
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1FLAG-mitoxantrone combined with low-dose venetoclax (7 Days): A highly efficient regimen and excellent bridge for allogeneic hematopoietic transplant for newly diagnosed and relapsed/refractory AML.2025
  2. 2High remission rates with FLAG-ida-venetoclax in acute myeloid leukemia: “Less is More” on days of venetoclax in the intensive regimen2025
  3. 3FLAG-IDA + venetoclax in newly diagnosed (ND) or relapsed/refractory (RR) AML.2024 · 18 citations
  4. 4Venetoclax Combined With FLAG ‐ IDA in Refractory or Relapsed Acute Myeloid Leukemia2024 · 9 citations
  5. 5Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation2025